treatment of rare (orphan) diseases by a decision of the central executive authority in charge of shaping the state policy in the field of healthcare. This provision shall be applied only to medicinal products designed solely for the treatment of rare (orphan) diseases, which are, according to the established procedure, authorised for use in the United States of America or in the Member States of the European Union, regardless of whether they are registered as medicinal products by the competent authorities of the United States of America or the European Union.